Alliancebernstein L.P. Sells 283,287 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Alliancebernstein L.P. lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 27.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 733,367 shares of the company's stock after selling 283,287 shares during the quarter. Alliancebernstein L.P. owned 0.34% of Hims & Hers Health worth $17,733,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HIMS. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Hims & Hers Health during the 4th quarter valued at approximately $254,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of Hims & Hers Health during the 4th quarter worth about $208,000. Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $38,000. Arrowstreet Capital Limited Partnership raised its holdings in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Finally, DnB Asset Management AS boosted its position in Hims & Hers Health by 116.0% during the fourth quarter. DnB Asset Management AS now owns 138,665 shares of the company's stock worth $3,353,000 after purchasing an additional 74,457 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Performance

Hims & Hers Health stock traded up $0.33 during trading on Monday, reaching $27.56. The company had a trading volume of 3,746,006 shares, compared to its average volume of 15,104,026. The firm has a market capitalization of $6.12 billion, a price-to-earnings ratio of 62.63 and a beta of 1.65. The stock's 50 day moving average price is $38.75 and its two-hundred day moving average price is $30.46. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Remove Ads

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on HIMS shares. Bank of America lifted their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an "underperform" rating in a research note on Tuesday, March 18th. Truist Financial dropped their price target on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday. Piper Sandler upped their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Finally, Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $38.25.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 36,460 shares of Hims & Hers Health stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the transaction, the chief executive officer now owns 27,918 shares in the company, valued at approximately $756,298.62. The trade was a 56.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 824,303 shares of company stock worth $31,376,661. Insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.